SOD1 and amyotrophic lateral sclerosis: Although AAV gene therapy is moving forward for ALS caused by SOD1 mutations, it is important to note that SOD1 mutations account for a small percentage of ALS cases, and it remains to be seen whether this therapy would also be beneficial to patients with sALS, as has been previously proposed46.